Intec Pharma Ltd (NASDAQ:NTEC) Director Anthony J. Maddaluna bought 25,000 shares of Intec Pharma stock in a transaction dated Tuesday, August 27th. The stock was acquired at an average cost of $0.47 per share, with a total value of $11,750.00. Following the completion of the acquisition, the director now directly owns 53,570 shares of the company’s stock, valued at approximately $25,177.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ NTEC traded up $0.08 during trading hours on Friday, hitting $0.74. 1,392,640 shares of the stock were exchanged, compared to its average volume of 2,300,061. Intec Pharma Ltd has a 12-month low of $0.41 and a 12-month high of $9.25. The stock has a 50-day moving average of $0.67 and a 200 day moving average of $4.65.
NTEC has been the subject of a number of research reports. Maxim Group cut shares of Intec Pharma from a “buy” rating to a “hold” rating in a report on Monday, July 22nd. ValuEngine raised shares of Intec Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Oppenheimer cut shares of Intec Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, July 22nd. HC Wainwright cut shares of Intec Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Finally, LADENBURG THALM/SH SH reaffirmed a “hold” rating on shares of Intec Pharma in a report on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $12.17.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Read More: NASDAQ
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.